Evidence map›Paper›PMID 31692649›Full record

ArticleTherapeutic advances in musculoskeletal disease2019

Zoledronic acid plus methylprednisolone

Guoqi Cai, Laura L Laslett, Dawn Aitken, Flavia Cicuttini, Lyn March, Catherine Hill, Tania Winzenberg, Graeme Jones

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Guoqi CaiMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.ORCID https://orcid.org/0000-0002-6481-704X
Laura L LaslettMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Dawn AitkenMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Flavia CicuttiniDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Lyn MarchRoyal North Shore Hospital, University of Sydney, Sydney, Australia.
Catherine HillDepartment of Rheumatology, the Queen Elizabeth Hospital, Adelaide, Australia.
Tania WinzenbergMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Graeme JonesMenzies Institute for Medical Research, University of Tasmania, Private Bag 23, Hobart, Tasmania 7000, Australia.
University of Tasmania · AUMonash University · AUQueen Elizabeth Hospital · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to compare the efficacy and safety of zoledronic acid (ZA) plus intravenous methylprednisolone (VOLT01) to ZA, and placebo for knee osteoarthritis.

methodsA single-center, double-blind, randomized controlled trial (RCT) was carried out. Adults (aged ⩾50 years) with knee osteoarthritis, significant knee pain [⩾40 mm on a 100 mm visual analog scale (VAS)], and magnetic resonance imaging-detected bone marrow lesion (BML) were randomized to receive a one-off administration of VOLT01, ZA, or placebo. The primary hypothesis was that VOLT01 was superior to ZA in having a lower incidence of acute phase responses (APRs) over 3 days. Secondary hypotheses were that VOLT01 was noninferior to ZA, and both treatments were superior to placebo in decreasing BML size over 6 months and in improving knee pain [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and VAS] and function (WOMAC) over 3 and 6 months.

resultsA total of 117 patients (62.2 ± 8.1 years, 63 women) were enrolled. The incidence of APRs was similar in the VOLT01 (90%) and ZA (87%) groups (

conclusionsAdministering intravenous methylprednisolone with ZA did not reduce APRs or change knee BML size over 6 months, but in contrast to ZA or placebo, it may have a beneficial effect on symptoms in knee osteoarthritis.

trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12613000039785.

Indexed as

acute phase responsebone marrow lesionmethylprednisolonenoninferiorityzoledronic acid

Identifiers

PMID31692649
PMCPMC6811759
OpenAlexW2982024520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.